Drug intelligence / Profile preview

YD06-1

Development stage: Phase 1
Lead developer: West China Hospital of Sichuan University
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
Administration: Intratumoral

Overview

YD06-1 is a genetically engineered oncolytic herpes simplex virus type 1 (oHSV-1) developed by West China Hospital of Sichuan University for the treatment of advanced solid tumors. The virus is designed to selectively replicate within and lyse malignant cells while sparing healthy tissue. Beyond direct viral-mediated cell death, YD06-1 aims to stimulate a systemic anti-tumor immune response by releasing tumor-associated antigens and promoting an inflammatory microenvironment. It is currently being evaluated in Phase 1 clinical trials, both as a monotherapy and in combination with other oncolytic agents such as SDJ001.

Other names: recombinant oncolytic herpes simplex virus type 1 YD06-1

Beyond the preview

Go deeper on YD06-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YD06-1.

Explore the full profile